The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure.

• Type of Material: Article
• Authors: David J. Polhemus, LSU Health Sciences Center; John Calvert, Emory University; Javed Butler, Emory University; David J. Lefer, LSU Health Sciences Center
• Language: English
• Date: 2014-06-22
• Publisher: Hindawi Publishing Corporation
• Publication Version: Final Published Version
• Copyright Statement: © 2014 David J. Polhemus et al.
• License: Creative Commons Attribution 3.0 Unported
• Final Published Version (URL): http://dx.doi.org/10.1155/2014/768607
• Title of Journal or Parent Work: Scientifica
• ISSN: 2090-908X
• Volume: 2014
• Start Page: 768607
• End Page: 768607
• Grant/Funding Information: This work was supported by Grants from the National Heart, Lung, and Blood Institute (National Institutes of Health; 1R01 HL092141, 1R01 HL093579, 1U24 HL 094373, and 1P20 HL113452 to David J. Lefer).; The authors are also grateful for the generous funding support from TEVA USA Scholars Program and the LSU Medical School Alumni Association.
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Pharmacology

Abstract

It has now become universally accepted that hydrogen sulfide (H2S), previously considered only as a lethal toxin, has robust cytoprotective actions in multiple organ systems. The diverse signaling profile of H2S impacts multiple pathways to exert cytoprotective actions in a number of pathological states. This paper will review the recently described cardioprotective actions of hydrogen sulfide in both myocardial ischemia/reperfusion injury and congestive heart failure.